• In the second quarter of 2026, Glaukos Corporation reported sales of US$185.61 million versus US$124.12 million a year earlier, with its basic loss per share from continuing operations narrowing to US$0.31 from US$0.34.
• Alongside this performance, Glaukos raised its 2026 net sales guidance to a range of US$680 million to US$700 million, signaling management’s increased confidence in the company’s revenue outlook despite ongoing losses.
• We’ll now explore how Glaukos’ raised full-year sales guidance reshapes its existing investment narrative and the balance between growth and losses.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Glaukos Investment Narrative Recap

To own Glaukos, you need to believe its glaucoma and corneal franchises can eventually justify ongoing losses and a premium valuation. The key near term catalyst is continued uptake of its newer therapies, while the biggest risk remains reimbursement and pricing pressure. The latest results and higher 2026 sales guidance strengthen the near term revenue story but do not fundamentally change the concern that Glaukos is still loss making and reliant on supportive reimbursement.

Among recent announcements, the new CMS J code for Epioxa and Epioxa HD stands out in light of Glaukos’ raised sales outlook. By simplifying billing and reimbursement for keratoconus treatment, this coding decision directly connects to the main short term catalyst: converting clinical demand for newer products into reimbursed revenue. It also sits alongside the broader risk that any reversal or tightening of reimbursement support could quickly affect volumes and margins.

Yet despite the stronger revenue outlook, investors should be aware that reimbursement decisions can still shift suddenly and...

Glaukos' narrative projects $1.1 billion revenue and $113.0 million earnings by 2029.

Uncover how Glaukos' forecasts yield a $165.00 fair value, a 9% downside to its current price.

Exploring Other Perspectives

While consensus sees growth supported by glaucoma and corneal therapies, the most pessimistic analysts were only expecting about US$891 million revenue and US$61 million earnings by 2029, so this guidance beat could eventually nudge even those tougher views, depending on how you weigh reimbursement and competition risks.

Explore 4 other fair value estimates on Glaukos - why the stock might be worth 25% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Glaukos research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Glaukos research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Glaukos' overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 57 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.